Cyclacel Pharmaceuticals, Inc.
CYCC
$7.99
-$0.01-0.13%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,527.16% | 97.35% | -55.95% | 39.91% | -10.56% |
| Total Depreciation and Amortization | -- | -- | 0.00% | -50.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 195.82% | 1,701.08% | -8.82% | -41.04% | -7.49% |
| Change in Net Operating Assets | 3.04% | -402.18% | 232.07% | -60,550.00% | -100.09% |
| Cash from Operations | 67.48% | -139.45% | 55.79% | 0.55% | -538.51% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -57.04% | 141.41% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | -- | -- | -- | 200.00% |
| Cash from Financing | -48.44% | 126.04% | 161,400.00% | -100.02% | 8,060.76% |
| Foreign Exchange rate Adjustments | 101.16% | 15.69% | -304.00% | 1,766.67% | 83.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 163.58% | 101.94% | 105.14% | -194.25% | 652.07% |